(fifthQuint)AdHerencE to Treatment and quAlity of Life in COPD.

 Rolenium(R) is an inhalable combination the active ingredients of which is the inhaled combination of fluticasone propionate and salmeterol in doses (100 + 50) mcg, (250 + 50) mcg, (500 + 50) mcg administered via the Elpenhaler (R), developed by ELPEN.

 It has been approved as a bronchodilator therapy for COPD (a fast-exiting volume in the first second (FEV1) after a bronchodilator less than 60% predicted) with a history of repeated seizures that have significant symptoms despite regular bronchodilator therapy.

 For COPD in adults an inhalation of 500 micrograms of fluticasone propionate and 50 micrograms of salmeterol twice daily is recommended4.

 More information on the efficacy and safety of the investigational medicinal product is provided in the Summary of Product Characteristics (SPC).

.

 AdHerencE to Treatment and quAlity of Life in COPD@highlight

The present non-interventional observational study in the Greek population aims at collecting the characteristics of COPD patients selected to be given the inhaled combination of fluticasone propionate and salmeterol in doses of 100 1/2g mcg (250 1/2g) mcg (500 g) mcg through the Elpenhaler(R) device, to investigate (a) the effectiveness of the treatment for compliance and the quality of life of the patients; and (b) the safety of the drugs in patients whose disease is treated either in a hospital or in a private physician.

